Indian Journal of Medical Biochemistry

Register      Login

VOLUME 21 , ISSUE 1 ( January-June, 2017 ) > List of Articles


Immune Response Profiling of Patients with Anogenital Warts

Manjula Singh, Deepshi Thakral, Hemanta K Kar, Narayan Rishi, Dipendra K Mitra

Citation Information : Singh M, Thakral D, Kar HK, Rishi N, Mitra DK. Immune Response Profiling of Patients with Anogenital Warts. Indian J Med Biochem 2017; 21 (1):11-16.

DOI: 10.5005/jp-journals-10054-0011

License: CC BY 3.0

Published Online: 01-12-2012

Copyright Statement:  Copyright © 2017; The Author(s).


How to cite this article

Singh M, Thakral D, Kar HK, Rishi N, Mitra DK. Immune Response Profiling of Patients with Anogenital Warts. Indian J Med Biochem 2017;21(1):11-16.

  1. A retrospective study of the pattern of sexually transmitted diseases during a ten-year period. Indian J Dermatol Venereol Leprol 2005 Sep-Oct;71(5):333–337.
  2. Diagnostic pathology: infectious diseases. Philadelphia (PA): Elsevier Health Sciences; 2015. p. 40.
  3. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995 Aug;33(8):2058–2063.
  4. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl) 2004 Feb;193(1):35–44.
  5. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003 Jun;36(11):1397–1403.
  6. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 1997 Aug;176(2):353–361.
  7. Burden of human papillomavirus infection and related co-morbidities in men: implications for research, disease prevention and health promotion among Hispanic men. P R Health Sci J 2010 Sep;29(3):232–240.
  8. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007 Oct;196(8):1128–1136.
  9. Genital warts treated by photodynamic therapy. Skinmed 2007 Nov-Dec;6(6):295–297.
  10. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008 May;109(2 Suppl):S15–S21.
  11. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013 Nov;5(11):2624–2642.
  12. Immune response against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 2012 Dec;18(6): 807–815.
  13. Cellular subsets and epithelial ICAM-1 and HLA-DR expression in human papillomavirus infection of the vulva. Acta Derm Venereol 1994 Jan;74(1):45–50.
  14. Immunohistochemical and ultrastructural features of Langerhans cells in condyloma acuminatum. J Cutan Pathol 2008 Jan; 35(1):15–20.
  15. Decreased Langerhans cell responses to IL-36□: altered innate immunity in patients with recurrent respiratory papillomatosis. Mol Med 2014 Aug;20:372–380.
  16. Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminate. J Immunol 2008 Jun;180(11):7681–7686.
  17. Immunological study on genital wart patients in Babylon Province – Iraq. Med J Babylon 2015 May;12(1):233–239.
  18. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997 Feb;89(3):245–250.
  19. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol 2012 Sep;73(9):920–926.
  20. Serological studies with human papova (wart) virus. J Hyg (Lond) 1970 Sep;68(3):479–490.
  21. Characterisation of the virus found in human genital warts. Microbios 1969;3:225–233.
  22. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984 Oct;150(3):300–308.
  23. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrol Dial Transplant 1994 Jan;9(4):416–420.
  24. Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995 Feb;139:69–86.
  25. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999; 20(2):127–130.
  26. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 1998 Jul;12(10):1177–1184.
  27. Association of human immunodeficiency virus and anal human papillomavirus infection among homosexual men. Arch Intern Med 1992 Aug;152(8):1673–1676.
  28. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS 1996 Dec;10(14):1641–1647.
  29. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 1990 Jun;263(21):2911–2916.
  30. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med 1997 Jun;73(3):174–180.
  31. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998 Feb;177(2):361–367.
  32. Human papillomavirus infections of the genital region in human immunodeficiency virus seropositive women: integration of type 16 correlates with rapid progression. Eur J Gynaecol Oncol 1994 Jan;15(1):50–58.
  33. A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. Infect Dis Obstet Gynecol 1999 Jan;7(3):158–164.
  34. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998 May;178(5):982–986.
  35. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997 Nov;337(19):1343–1349.
  36. Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-alpha. J Immunol 1992 Oct;149(8):2702–2708.
  37. Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-alpha-mediated growth limitation. Int J Cancer 1994 Feb;56(4):593–598.
  38. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 1990 Oct;64(10):4767–4775.
  39. In vitro assay of cell-mediated immunity to human wart antigen. Br J Dermatol 1974 May;90(5):531–534.
  40. In vitro lymphocyte stimulation by wart antigen in man. Br J Dermatol 1976 May;94(5):523–527.
  41. Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens. Clin Exp Immunol 1976 Dec;26(3):419–424.
  42. Specific immunity in patients suffering from recurring warts before and after repetitive intradermal tests with human papilloma virus. Br J Dermatol 1997 Oct;97(4):365–370.
  43. A comparative study of delayed hypersensitivity skin reactions and antibodies to human papilloma virus (HPV). Clin Exp Immunol 1997 Aug;29(2):240–246.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.